Stock comparison
Abbott Laboratories
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 77B | LMAT |
| Benjamin Graham | 69B | 89A | LMAT |
| Philip Fisher | 46D | 81C | LMAT |
| Peter Lynch | 24F | 67B | LMAT |
| Joel Greenblatt | 42D | 56D | LMAT |
| Charlie Munger | 57C | 68D | LMAT |
| Terry Smith | 54D | 69D | LMAT |
Side-by-side metrics
| Metric | ABT | LMAT |
|---|---|---|
| Market cap | $152.25B | $2.23B |
| P/E (TTM) | 23.5x | 37.1x |
| EV/EBIT | 21.7x | 36.6x |
| ROIC (TTM) | 6.56% | 9.43% |
| Gross margin | 56.38% | 72.39% |
| Net margin | 13.91% | 24.35% |
| Revenue CAGR 5y | 0.72% | 12.75% |
| EPS CAGR 5y | -1.48% | 19.04% |
| Debt / Equity | 0.7x | 0.5x |
| Dividend yield | 2.89% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Market cap$152.25Bvs $2.23B+99%
- Dividend yield2.89%vs 0.84%+71%
- EV/EBIT21.7xvs 36.6x+41%
- P/E (TTM)23.5xvs 37.1x+37%
LMAT leads on
- EPS CAGR 5y19.04%vs -1.48%+108%
- Revenue CAGR 5y12.75%vs 0.72%+94%
- Net margin24.35%vs 13.91%+43%
- ROIC (TTM)9.43%vs 6.56%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.